secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0000950170-24-050525
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q1 net loss $22.5M; ENLIGHTEN 1 Phase 3 results expected in May 2024
--------------------------------------------------------------------------------

- Cash $87.1M at March 31, 2024 vs $102.8M at Dec 31, 2023; cash runway into Q1 2025.
- Net loss $22.5M vs $16.3M in Q1 2023; R&D expense $18.2M (up $5.6M YoY).
- ENLIGHTEN 1 pivotal Phase 3 data for LYR-210 in CRS expected in May 2024.
- ENLIGHTEN 2 enrollment completion expected H2 2024; LYR-220 end-of-Phase 2 meeting with FDA anticipated H2 2024.
- BEACON Phase 2 data for LYR-220 to be presented at COSM on May 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/0000950170-24-050525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/lyra-20240430.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-050525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer